Clareo Health | Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
JSehouli
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed epithelial ovarian cancer, primary peritoneal carcinomatosis or fallopian tube cancer
Recurrent ovarian cancer disease
Signs for progression either measurable disease according to RECIST or CA 125 increase according the GCIG-criteria or clinical symptoms of tumor progression according to RECIST
Radiologically and cytologically confirmed malignant ascites possible to puncture
Life expectancy ≥ 12 weeks
Age ≥ 18 years
ECOG performance status at least 1
No prior operation or, in case of prior operation, the patient must be recovered therefrom. The operation must be performed at least 4 weeks prior to start of study drug
Capable of understanding the purposes and risks of the study, willing and able to participate in the study, and written informed consent
Non-childbearing potential or negative pregnancy test
You may not be if
known brain metastases
Concomitant cancer, chemo- or radiotherapy (except for local radiation therapy for bone marrow metastases)
Any investigational product within 2 weeks prior to first administration of catumaxomab
In cases of previous exposure to investigational product, cancer-, chemo-, immune- or radiotherapy (except for local radiation therapy for bone marrow metastasis):
Patients must not have been exposed to nitrosoureas or mitomycin C within 6 weeks prior the first infusion of catumaxomab
Abnormal organ or bone marrow function
Use of immune-suppressive agents for the past 4 weeks prior to first administration of catumaxomab. For regular use of systemic corticosteroids patients should only be included after stepwise discontinuation to be free of steroids for a minimum of 5 days prior to study entry
Any known active and chronic infection
Known HIV infection and / or hepatitis B virus or hepatitis C virus
Any other concurrent disease or medical conditions that are deemed to interfere with the conduct of the study as judged by the investigator
Known or suspected hypersensitivity to catumaxomab and its analogues in general or to murine proteins (from rat or mouse)
Known or suspected hypersensitivity to PLD, topotecan, paclitaxel, gemcitabine or their excipients.
Patients with congestive heart failure New York Heart Association (NYHA) Class III and IV. Cardiac arrhythmias (except atrioventricular block type I and II, atrial fibrillation/flutter bundle brunch block)or other signs and symptoms of relevant cardiovascular disease
Body mass index (BMI) \< 17 (assessment after ascites drainage)
Inadequate respiratory function in the opinion of the investigator
Presence of complete bowel obstruction
Patients with substance abuse, medical or psychological or social conditions which the investigator believes would preclude compliance with the study requirements.
Unwilling or unable to follow protocol requirements
Participation in another clinical study with experimental therapy within 14 days before start of treatment
Legal incapacity or limited legal capacity
Subjects housed in an institution on official or legal orders
